Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 4/2009

01.08.2009

Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?

verfasst von: Bunyamin Yavuz, Derun Taner Ertugrul, Hicran Cil, Naim Ata, Kadir Okhan Akin, Ahmet Arif Yalcin, Metin Kucukazman, Kursad Dal, Murat Sevket Hokkaomeroglu, Burcu Balam Yavuz, Emre Tutal

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Low levels of 25-hydroxyvitamin D are associated with higher risk of cardiovascular morbidity and mortality. Large trials demonstrated that statins significantly decrease cardiovascular morbidity and mortality. 7-dehydrocholesterol is the precursor of both cholesterol and vitamin D. The aim of this study was to investigate the possible effect of rosuvastatin on vitamin D metabolism.

Methods

The study was performed in a prospective cohort design. The study group consisted of 91 hyperlipidemic patients who had not been treated with lipid lowering medications. Lipid parameters, 25 hydroxyvitamin-D, 1,25-dihydroxyvitamin D, and bone alkaline phosphatase were obtained at baseline and after 8 weeks of rosuvastatin treatment.

Results

None of the subjects withdrew from the study because of the adverse effects. The mean age was 59.9 ± 12.5 years. The majority of the patients were male (55, 60%). Seventeen patients were diabetic, and 43 patients had systemic hypertension. There was a significant increase in 25-hydroxyvitamin D, from mean 14.0 (range 3.7– 67) to mean 36.3 (range 3.8 –117) ng/ml (p < 0.001), and also an increase of 1,25-dihydroxyvitamin D from mean 22.9 ± 11.2 to 26.6 ± 9.3 pg/dl (p = 0.023). Bone alkaline phosphatase decreased after 8 weeks of rosuvastatin treatment, mean 17.7 (range 2.6–214) to mean 9.5 (range 2.3–19.1) u/l (p < 0.001) rosuvastatin treatment.

Conclusion

This study has shown an effect of rosuvastatin on vitamin D metabolism, with an increase in both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. This may be an important pleiotropic effect whereby rosuvastatin reduces mortality in patients with coronary artery disease. Further studies are needed to clarify the relationship between statins and vitamin D metabolism.
Literatur
1.
Zurück zum Zitat Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–80.2.PubMedCrossRef Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–80.2.PubMedCrossRef
2.
Zurück zum Zitat Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary heart disease. Q J Med. 1996;89:579–89. Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary heart disease. Q J Med. 1996;89:579–89.
3.
Zurück zum Zitat Mortimer EA, Monson RR, MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N EngI J Med. 1977;296:581–85.CrossRef Mortimer EA, Monson RR, MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N EngI J Med. 1977;296:581–85.CrossRef
4.
Zurück zum Zitat Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;3342:757–61.CrossRef Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;3342:757–61.CrossRef
5.
Zurück zum Zitat Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205–1209.PubMed Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205–1209.PubMed
6.
Zurück zum Zitat Shepherd J, Cobbe SM, Ford I, for the West of Scotland Coronary Prevention Study Group, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EngI J Med. 1995;333:1301–7.CrossRef Shepherd J, Cobbe SM, Ford I, for the West of Scotland Coronary Prevention Study Group, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EngI J Med. 1995;333:1301–7.CrossRef
7.
Zurück zum Zitat Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383–9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344:1383–9.
8.
Zurück zum Zitat Guryev O, Carvalho RA, Usanov S, Gilep A, Estabrook RW. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc NatI Acad Sci USA. 2003;100:14754–14759.CrossRef Guryev O, Carvalho RA, Usanov S, Gilep A, Estabrook RW. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc NatI Acad Sci USA. 2003;100:14754–14759.CrossRef
9.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486–97.CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285:2486–97.CrossRef
10.
Zurück zum Zitat Wilczek H, Sobra J, Justova V, Ceska R, Juzova Z, Prochazkova R, et al. latropathogenic effect of mevacor on vitamin D metabolism. Cas Lek Cesk. 1989;128:1254–1256.PubMed Wilczek H, Sobra J, Justova V, Ceska R, Juzova Z, Prochazkova R, et al. latropathogenic effect of mevacor on vitamin D metabolism. Cas Lek Cesk. 1989;128:1254–1256.PubMed
11.
Zurück zum Zitat Wilzcek H, Sobra J, Ceska R, Justota V, Juzova Z, Prochazkova R, et al. Monitoring plasma levels of vitamin D metabolites in simvastatin therapy in patients with familial hypercholesterolemia. Cas Lek Cesk. 1994;133:727–729. Wilzcek H, Sobra J, Ceska R, Justota V, Juzova Z, Prochazkova R, et al. Monitoring plasma levels of vitamin D metabolites in simvastatin therapy in patients with familial hypercholesterolemia. Cas Lek Cesk. 1994;133:727–729.
12.
Zurück zum Zitat Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99:903–5.PubMedCrossRef Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99:903–5.PubMedCrossRef
13.
Zurück zum Zitat Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering — are they clinically relevant? Eur Heart J. 2003;24:225–48.PubMedCrossRef Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering — are they clinically relevant? Eur Heart J. 2003;24:225–48.PubMedCrossRef
15.
Zurück zum Zitat Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–37.PubMedCrossRef Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629–37.PubMedCrossRef
16.
Zurück zum Zitat Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int. 2005;16:990–998.PubMedCrossRef Hatzigeorgiou C, Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int. 2005;16:990–998.PubMedCrossRef
17.
Zurück zum Zitat Safaei H, Janghorbani M, Aminorroaya A, Amini M. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007;44:76–82.PubMedCrossRef Safaei H, Janghorbani M, Aminorroaya A, Amini M. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007;44:76–82.PubMedCrossRef
18.
Zurück zum Zitat Uysal AR, Delibasi T, Erdogan MF, et al. Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract. 2007;13:114–6.PubMed Uysal AR, Delibasi T, Erdogan MF, et al. Effect of simvastatin use on bone mineral density in women with type 2 diabetes. Endocr Pract. 2007;13:114–6.PubMed
19.
Zurück zum Zitat Svejda P, Soska V, Soucek M. The impact of statin therapy on bone density changes in postmenopausal women. Vnitr Lek. 2007;53:1064–70.PubMed Svejda P, Soska V, Soucek M. The impact of statin therapy on bone density changes in postmenopausal women. Vnitr Lek. 2007;53:1064–70.PubMed
20.
Zurück zum Zitat Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM. Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int. 2005;16:1272–1276.PubMedCrossRef Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM. Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int. 2005;16:1272–1276.PubMedCrossRef
21.
Zurück zum Zitat Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur J Clin Invest. 2002;32:581–589.PubMedCrossRef Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: A cross-sectional study. Eur J Clin Invest. 2002;32:581–589.PubMedCrossRef
22.
Zurück zum Zitat Kajinami K, Takekoshi N, Matsui S, Kanemitsu S, Okubo S, Kanayama S, et al. Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1113–1116.PubMedCrossRef Kajinami K, Takekoshi N, Matsui S, Kanemitsu S, Okubo S, Kanayama S, et al. Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1113–1116.PubMedCrossRef
Metadaten
Titel
Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?
verfasst von
Bunyamin Yavuz
Derun Taner Ertugrul
Hicran Cil
Naim Ata
Kadir Okhan Akin
Ahmet Arif Yalcin
Metin Kucukazman
Kursad Dal
Murat Sevket Hokkaomeroglu
Burcu Balam Yavuz
Emre Tutal
Publikationsdatum
01.08.2009
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2009
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-009-6181-8

Weitere Artikel der Ausgabe 4/2009

Cardiovascular Drugs and Therapy 4/2009 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.